Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.58 USD

1.58
1,271,998

+0.04 (2.60%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.58 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

by Zacks Equity Research

Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

by Zacks Equity Research

New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 89.47% and 7.55%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 1.07% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts

by Zacks Equity Research

A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of -29.41% and 5.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.

Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval

by Zacks Equity Research

Lexicon's (LXRX) shares rise as it receives FDA approval for Inpefa, a once-daily oral tablet to treat a broad population of heart failure patients.

The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals

by Zacks Equity Research

Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.

Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More

by Zacks Equity Research

Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.

Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug

by Zacks Equity Research

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 18.75% and 680.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 11.76% and -99.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Lexicon Pharmaceuticals (LXRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 82.14% and 15.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

by Zacks Equity Research

Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.

Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

by Zacks Equity Research

Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.